
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
我們正在追蹤 Novo Nordisk 的市場擴張
過去 90 日內有 315 個訊號。
Novo Nordisk 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Novo Nordisk你 | 0 | 0 | — | 0 | 0 |
Supervisor, Business Intelligence
查看招聘Taipei, Taipei City, Taiwan · 今日
Senior IT/OT Solution Architect - API Expansion
查看招聘Kalundborg, Region Zealand, Denmark · 今日
Pharma Field Sales - Cardiometabolic Care Specialist I - P Bakersfield North California
查看招聘Bakersfield, CA · 5日前
Talk to a doctor
已結束Talk to a doctor
已結束Talk to a doctor
已結束巴西製藥公司EMS將於6月15日推出國產司美格魯肽,每支售價452雷亞爾,比Ozempic等進口產品便宜30%,使肥胖治療更易獲得。
康霈生技於ADA 2026發表CBL-514動物實驗數據,顯示與GLP-1/RA類藥物併用可將復胖率降低2.7倍,肝臟脂肪額外減少106.7%。
諾和諾德在中國推出諾澤優(帕西生長激素),為2.5歲以上生長激素缺乏兒童提供每週一次治療選擇,採用創新脂肪酸技術及零PEG配方。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Novo Nordisk 業務、市場及增長訊號的快速解答。
